Getting your player ready...
Replidyne Inc., the Louisville-based developer of an experimental drug for bronchitis, said it cut 35 percent of its workforce and suspended work on an antibiotic, moves aimed at helping the company stay in business at least two more years.
The company expects to hold advanced clinical trials of the bronchitis drug, faropenem, although it won’t sign up patients to test additional uses “until a partner is identified,” Replidyne said Monday in a statement.
Replidyne also said it will keep “key research and development expertise” to advance an experimental drug to fight disease caused by the bacterium C.-difficile.
